论文部分内容阅读
目的观察来曲唑内分泌治疗对晚期卵巢癌中位无进展生存时间(PFS)的影响。方法 2010年1月至2012年1月收治的47例晚期卵巢癌患者在经全身化疗达CR后,随机分为两组,治疗组24例给予来曲唑口服2.5 mg/d,直至病情进展,对照组23例不做内分泌治疗。结果随访截止时间为2013年10月30日,两组均无失访患者。治疗组来曲唑使用时间(24.5±7.4)个月,至随访截止时间治疗组有8例因病情进展而进入化疗治疗,其余患者继续采用来曲唑治疗;治疗组24例PFS为3~21个月,中位PFS为13个月;对照组23例患者PFS为1~15个月,中位PFS为10个月;两组PFS比较差异有统计学意义(P<0.05)。结论来曲唑治疗晚期卵巢癌有一定疗效,有利于延长患者的PFS。
Objective To observe the influence of letrozole endocrine therapy on the median progression-free survival time (PFS) of advanced ovarian cancer. METHODS: Forty-seven patients with advanced ovarian cancer who were admitted to our hospital from January 2010 to January 2012 were randomly divided into two groups after receiving CR for systemic chemotherapy. In the treatment group, 24 patients received letrozole 2.5 mg once daily until the disease progressed, The control group of 23 patients did not do endocrine therapy. Results The follow-up deadline was October 30, 2013, with no patient lost in both groups. In the treatment group, letrozole was used for 24.5 ± 7.4 months. Until the end of the follow-up period, 8 patients entered the chemotherapy group due to the progression of the disease and the rest patients continued to receive letrozole. The PFS of the 24 patients in the treatment group was 3 to 21 Months, the median PFS was 13 months; 23 patients in the control group PFS was 1 to 15 months, the median PFS was 10 months; PFS difference between the two groups was statistically significant (P <0.05). Conclusion Letrozole has a certain curative effect on advanced ovarian cancer, which is beneficial to prolong the PFS.